T-THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $133 MILLION SERIES B FINANCING TO ACHIEVE CLINICAL PROOF-OF-CONCEPT FOR FIRST-IN-CLASS TCR BISPECIFIC THERAPIES IN CANCER AND AUTOIMMUNE DISEASE

Reuters · 2d ago

Please log in to view news